ArticleLaboratory investigation; a journal of technical methods and pathology2022

Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma.

Polona Safaric Tepes et al.PubMed ↗Publisher ↗

No numbers read from the abstract.